CL2008001099A1 - Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras. - Google Patents

Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras.

Info

Publication number: CL2008001099A1
Authority: CL; Chile
Prior art keywords: indazol; diabetes; receptors; multiple sclerosis; autoimmune disease
Prior art date: 2007-04-19

Application number

CL200801099A

Other languages

English (en)

Inventor

Mahmood Ahmed

Gerard Martin Paul Giblin

James Myatt

David Norton

Dean Andrew Rivers

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-19

Filing date

2008-04-17

Publication date

2008-10-24

2007-04-19 Priority claimed from GB0707617A external-priority patent/GB0707617D0/en

2008-04-02 Priority claimed from GB0805993A external-priority patent/GB0805993D0/en

2008-04-17 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2008-10-24 Publication of CL2008001099A1 publication Critical patent/CL2008001099A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Neurology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Obesity (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

CL200801099A 2007-04-19 2008-04-17 Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras. CL2008001099A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB0707617A GB0707617D0 (en)	2007-04-19	2007-04-19	Compounds
GB0805993A GB0805993D0 (en)	2008-04-02	2008-04-02	Compounds

Publications (1)

Publication Number	Publication Date
CL2008001099A1 true CL2008001099A1 (es)	2008-10-24

Family

ID=39604751

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200801099A CL2008001099A1 (es)	2007-04-19	2008-04-17	Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras.

Country Status (24)

Country	Link
US (1)	US8324254B2 (es)
EP (1)	EP2137181B1 (es)
JP (1)	JP5313229B2 (es)
KR (1)	KR20090130062A (es)
AR (1)	AR066095A1 (es)
AT (1)	ATE500252T1 (es)
AU (1)	AU2008240773B2 (es)
BR (1)	BRPI0809472A2 (es)
CA (1)	CA2684385A1 (es)
CL (1)	CL2008001099A1 (es)
CO (1)	CO6321136A2 (es)
CR (1)	CR11119A (es)
DE (1)	DE602008005285D1 (es)
DO (1)	DOP2009000237A (es)
EA (1)	EA016443B1 (es)
IL (1)	IL200870A (es)
JO (1)	JO2686B1 (es)
MA (1)	MA31311B1 (es)
MX (1)	MX2009011155A (es)
MY (1)	MY146606A (es)
NZ (1)	NZ579595A (es)
PE (1)	PE20090150A1 (es)
TW (1)	TWI408137B (es)
WO (1)	WO2008128951A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2648303C (en)	2006-04-03	2014-07-15	Astellas Pharma Inc.	5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists
JO2701B1 (en) *	2006-12-21	2013-03-03	جلاكسو جروب ليميتد	Vehicles
US20100273806A1 (en) *	2007-12-18	2010-10-28	Arena Pharmaceuticals, Inc.	Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
JP5449320B2 (ja) *	2008-04-04	2014-03-19	イーライリリーアンドカンパニー	３−インダゾリル−４−ピリジルイソチアゾール類
GB0807910D0 (en)	2008-04-30	2008-06-04	Glaxo Group Ltd	Compounds
CN102105144B (zh) *	2008-07-23	2013-11-13	诺华股份有限公司	鞘氨醇1磷酸酯受体调节剂以及它们用于制备治疗肌肉炎症的药物的用途
KR20210099206A (ko)	2008-07-23	2021-08-11	아레나 파마슈티칼스, 인크.	자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
JP5731385B2 (ja)	2008-08-22	2015-06-10	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	ポリマーベンジルカルボネート誘導体
SI2342205T1 (sl)	2008-08-27	2016-09-30	Arena Pharmaceuticals, Inc.	Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj
BRPI0919004A2 (pt)	2008-09-22	2019-09-24	Cayman Chem Co	composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
BRPI0923178A2 (pt) *	2008-12-18	2016-02-16	Merck Serono Sa	derivados heterocíclicos de oxadiazol fundidos úteis para o tratamento de esclerose múltipla
GB0910691D0 (en) *	2009-06-19	2009-08-05	Glaxo Group Ltd	Novel compounds
GB0910674D0 (en)	2009-06-19	2009-08-05	Glaxo Group Ltd	Novel compounds
GB0910689D0 (en) *	2009-06-19	2009-08-05	Glaxo Wellcome Mfg Pte Ltd	Novel compounds
US8399451B2 (en) *	2009-08-07	2013-03-19	Bristol-Myers Squibb Company	Heterocyclic compounds
WO2011072488A1 (en) *	2009-12-18	2011-06-23	Glaxo Group Limited	Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
EP2528894A1 (en)	2010-01-27	2012-12-05	Arena Pharmaceuticals, Inc.	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
WO2011109471A1 (en)	2010-03-03	2011-09-09	Arena Pharmaceuticals, Inc.	Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
RU2014135795A (ru) *	2012-02-03	2016-03-27	Новартис Аг	Способ получения этилового эфира n-(4-циклогексил-3-трифторметилбензилокси)ацетимидовой кислоты
JP2016028016A (ja) *	2012-12-12	2016-02-25	大日本住友製薬株式会社	オキサジアゾール誘導体とその医薬用途
AU2014309817A1 (en) *	2013-08-20	2016-02-18	Meiji Seika Pharma Co., Ltd.	Methods for evaluating and screening S1P1 receptor agonists
KR20230151072A (ko)	2015-01-06	2023-10-31	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 상태의 치료 방법
CN108349891B (zh)	2015-06-22	2022-04-05	艾尼纳制药公司	用于s1p1受体相关病症的化合物的结晶l-精氨酸盐
MA47504A (fr)	2017-02-16	2019-12-25	Arena Pharm Inc	Composés et méthodes de traitement de l'angiocholite biliaire primitive
MA47503A (fr)	2017-02-16	2021-04-21	Arena Pharm Inc	Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
KR102859841B1 (ko)	2018-06-06	2025-09-12	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 병태의 치료 방법
CN109100971B (zh) *	2018-08-20	2024-02-09	合肥华耀电子工业有限公司	一种带互锁功能的开关机时序控制电路
KR102836433B1 (ko)	2018-09-06	2025-07-21	아레나 파마슈티칼스, 인크.	자가면역 및 염증성 장애의 치료에 유용한 화합물

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3939238A1 (de)	1989-11-28	1991-05-29	Bayer Ag	Heterocyclisch substituierte acrylsaeureester
US5262416A (en)	1990-01-28	1993-11-16	Bayer Aktiengesellschaft	Pesticidal substituted 2-[6-(pyrimidinyl)-indol-1-yl]-acrylic esters
US5462943A (en)	1990-01-28	1995-10-31	Bayer Aktiengesellschaft	Substituted acetic acid esters useful as pesticides per se and as intermediates for substitued acrylic esters pesticides
DE4002466A1 (de)	1990-01-28	1991-10-10	Bayer Ag	Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester
US5523312A (en)	1994-09-27	1996-06-04	Sterling Winthrop Inc.	Antipicornaviral agents
JPH1180026A (ja)	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
JP2001199983A (ja) *	2000-01-18	2001-07-24	Teijin Ltd	ベンズイミダゾール誘導体
CA2488117A1 (en)	2002-06-17	2003-12-24	Merck & Co., Inc.	1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
JP4638410B2 (ja) *	2003-04-30	2011-02-23	ノバルティスアーゲー	スフィンゴシン−１−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体
AU2004240586A1 (en) *	2003-05-15	2004-12-02	Merck & Co., Inc.	3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
CN1859908A (zh)	2003-10-01	2006-11-08	默克公司	作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
CN1894225A (zh)	2003-12-17	2007-01-10	默克公司	作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
US8039674B2 (en)	2004-06-23	2011-10-18	Ono Pharmaceutical Co., Ltd.	Compound having S1P receptor binding potency and use thereof
US7659294B2 (en)	2004-10-22	2010-02-09	Merck & Co., Inc.	2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
NZ560513A (en)	2005-02-25	2010-07-30	Ono Pharmaceutical Co	Indole compound and use thereof
AU2006226020A1 (en)	2005-03-23	2006-09-28	Actelion Pharmaceuticals Ltd.	Novel thiophene derivatives as sphingosine-l-phosphate-1 receptor agonists
JPWO2006115188A1 (ja)	2005-04-22	2008-12-18	第一三共株式会社	ヘテロ環化合物
EP1893591A1 (en)	2005-06-08	2008-03-05	Novartis AG	POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
MX2008002540A (es) *	2005-08-23	2008-03-14	Irm Llc	Compuestos inmunosupresores y composiciones.
GB0601744D0 (en) *	2006-01-27	2006-03-08	Novartis Ag	Organic compounds
CA2648303C (en)	2006-04-03	2014-07-15	Astellas Pharma Inc.	5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists
JO2701B1 (en) *	2006-12-21	2013-03-03	جلاكسو جروب ليميتد	Vehicles

2008
- 2008-04-17 MX MX2009011155A patent/MX2009011155A/es active IP Right Grant
- 2008-04-17 AR ARP080101584A patent/AR066095A1/es not_active Application Discontinuation
- 2008-04-17 CL CL200801099A patent/CL2008001099A1/es unknown
- 2008-04-17 BR BRPI0809472-1A patent/BRPI0809472A2/pt not_active IP Right Cessation
- 2008-04-17 CA CA002684385A patent/CA2684385A1/en not_active Abandoned
- 2008-04-17 TW TW097113880A patent/TWI408137B/zh not_active IP Right Cessation
- 2008-04-17 PE PE2008000672A patent/PE20090150A1/es not_active Application Discontinuation
- 2008-04-17 AT AT08736315T patent/ATE500252T1/de not_active IP Right Cessation
- 2008-04-17 AU AU2008240773A patent/AU2008240773B2/en not_active Expired - Fee Related
- 2008-04-17 EA EA200970967A patent/EA016443B1/ru not_active IP Right Cessation
- 2008-04-17 JO JO2008183A patent/JO2686B1/en active
- 2008-04-17 DE DE602008005285T patent/DE602008005285D1/de active Active
- 2008-04-17 JP JP2010503494A patent/JP5313229B2/ja not_active Expired - Fee Related
- 2008-04-17 US US12/596,488 patent/US8324254B2/en not_active Expired - Fee Related
- 2008-04-17 WO PCT/EP2008/054647 patent/WO2008128951A1/en not_active Ceased
- 2008-04-17 MY MYPI20094368A patent/MY146606A/en unknown
- 2008-04-17 NZ NZ579595A patent/NZ579595A/en not_active IP Right Cessation
- 2008-04-17 EP EP08736315A patent/EP2137181B1/en not_active Not-in-force
- 2008-04-17 KR KR1020097021613A patent/KR20090130062A/ko not_active Ceased
2009
- 2009-09-10 IL IL200870A patent/IL200870A/en not_active IP Right Cessation
- 2009-10-08 DO DO2009000237A patent/DOP2009000237A/es unknown
- 2009-10-15 MA MA32280A patent/MA31311B1/fr unknown
- 2009-10-16 CO CO09115828A patent/CO6321136A2/es active IP Right Grant
- 2009-11-19 CR CR11119A patent/CR11119A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
IL200870A0 (en)	2010-05-17
TWI408137B (zh)	2013-09-11
AU2008240773B2 (en)	2013-10-03
DE602008005285D1 (de)	2011-04-14
MA31311B1 (fr)	2010-04-01
ATE500252T1 (de)	2011-03-15
EA016443B1 (ru)	2012-05-30
BRPI0809472A2 (pt)	2014-09-09
JO2686B1 (en)	2013-03-03
MX2009011155A (es)	2009-10-30
MY146606A (en)	2012-09-14
PE20090150A1 (es)	2009-05-08
DOP2009000237A (es)	2010-05-31
JP5313229B2 (ja)	2013-10-09
WO2008128951A1 (en)	2008-10-30
AU2008240773A1 (en)	2008-10-30
US8324254B2 (en)	2012-12-04
NZ579595A (en)	2012-06-29
TW200911794A (en)	2009-03-16
JP2010524886A (ja)	2010-07-22
CA2684385A1 (en)	2008-10-30
US20100113528A1 (en)	2010-05-06
KR20090130062A (ko)	2009-12-17
CR11119A (es)	2010-01-18
AR066095A1 (es)	2009-07-22
EA200970967A1 (ru)	2010-02-26
HK1138001A1 (en)	2010-08-13
CO6321136A2 (es)	2011-09-20
EP2137181B1 (en)	2011-03-02
EP2137181A1 (en)	2009-12-30
IL200870A (en)	2013-08-29

Similar Documents

Publication	Publication Date	Title
CL2008001099A1 (es)	2008-10-24	Compuestos derivados de indazol; y su uso para tratar enfermedades mediadas por los receptores s1p1, tales como esclerosis multiple, enfermedad autoinmune, trastornos inflamatorios, diabetes, entre otras.
CL2013003333A1 (es)	2015-02-27	Compuestos derivados de pregnenolona, antagonistas de receptor cb1; composicion farmaceutica: y su uso para el tratamiento de trastornos de la vejiga y gastrointestinales, enfermedades inflamatorias, cardiovasculares, entre otras.
CL2007002199A1 (es)	2008-03-07	Compuestos derivados de sulfonil amida, moduladores del receptor cb2; composicion farmaceutica; y su uso para tratar enfermedades inflamatorias y autoinmune.
ECSP11010932A (es)	2011-04-29	Compuestos de azaindazol como antagonistas del receptor de ccr1
CL2007002572A1 (es)	2008-04-18	Compuestos derivados de benzotiazol, moduladores de quinasa; composicion farmaceutica que los contiene; y su uso para el tratamiento de un trastorno mediado por la quinasa c-jun-n-terminal, tales como trastornos autoinmunes, inflamatorios, metabolico
CL2013003816A1 (es)	2014-06-20	Compuestos derivados de carboxamida y urea que comprende pirazol aromatico sustituido, ligantes del receptor de vanilloide; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o profilaxis del dolor, migraña, enfermedad de parkinson, trastornos gastrointestinales, osteoporosis, entre otras enfermedades.
CL2009000048A1 (es)	2009-11-20	Uso de compuestos derivados de triterpenoides en el tratamiento de insuficiencia renal, y enfermedades asociadas tales como: nefropatías, resistencia a la insulina, diabetes, patologías vasculares, entre otras.
CL2007003832A1 (es)	2008-07-25	Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades.
CL2007001887A1 (es)	2008-02-08	Compuestos derivados de bifensustuidas por tetrazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades asociadas con los receptores purinergicos de p2x, tales como trastornos gastrointes
SV2011003807A (es)	2011-03-23	Composiciones y metodos de uso para anticuerpos terapeuticos
CL2007003629A1 (es)	2008-08-08	Compuestos heterociclicos aril-sustituidos, moduladores del receptor de cannabinoides tipo i (cb1); proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos metabolicos y trastornos cognitivos.
HK1199259A1 (en)	2015-06-26	Lysophosphatidic acid receptor antagonists
EA201290964A1 (ru)	2013-05-30	Пептидные конъюгаты агонистов рецептора glp-1 и их применение
ECSP088874A (es)	2008-12-30	Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
CL2013002194A1 (es)	2014-01-31	Compuestos derivados de 1-(1-(quinazolin-2-il) o quinolin-2-il)metil-piperidina, 1-(naftalen-2-il)metil)-(piperidina o perhidro-azepina) y otros derivados de los mismos; su composicion farmaceutica; y uso como moduladores de la actividad de los receptores de s1p, en el tratamiento de esclerosis multiple, enfermedades autoinmunes, trastornos inflamatorios cronicos, asma, artritis, entre otras.
CL2011000071A1 (es)	2011-05-06	Compuestos derivados de oxazolopirimidinas, antagonistas del receptor edg-1; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades cardiovasculares, trombosis, aterosclerosis, hipertension, diabetes, enfermedades renales, respiratorias, inflamatorias y autoinmunes, entre otras.
CL2014003388A1 (es)	2015-04-10	Compuestos derivados de triazolona, como inhibidores de mpges-1; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, util para el tratamiento de inflamacion, asma, epoc, artritis, enfermedad de parkinson y enfermedades autoinmunes, entre otras enfermedades.
CL2008000690A1 (es)	2008-09-12	Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CL2008001994A1 (es)	2008-09-22	Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
CL2011000544A1 (es)	2011-06-17	Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades.
MX2020005645A (es)	2020-12-10	Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido.
DOP2006000162A (es)	2007-01-31	Nuevos anticuerpos anti-madcan
CL2008000198A1 (es)	2008-05-30	Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, trastorno de lipidos, obesidad y aterosclerosis.
CL2014001254A1 (es)	2014-10-10	Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes.
CL2008000593A1 (es)	2008-09-05	Uso de compuestos derivados de heterociclos sustituidos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad aterosclerotica de las arterias entre otras enfermedades.